UNSPSC 51262409: Amosulalol monohydrochloride

This classification denotes an adrenergic antagonist with the molecular formula C18H24N2O5S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4O4S698PEE, chemically known as benzenesulfonamide, 5-(1-hydroxy-2-((2-(2-methoxyphenoxy)ethyl)amino)ethyl)-2-methyl-, hydrochloride (1:1), but more generally known as amosulalol monohydrochloride, which bears US NIH Compound Identifier 123707.

European Medicines Agency schedules amosulalol monohydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05478MIG. Most nations, for tariff purposes, schedule amosulalol monohydrochloride under HS 29350090. SMILES: CC1CCC(CC1S(=O)(=O)N)C(CNCCOC2CCCCC2OC)O.CL.

UNSPSC 51262409 Amosulalol monohydrochloride is a Commodity code that encompasses pharmaceutical products, though recent state and local solicitations tagged under it show minimal alignment with the code's nominal scope. The two recent opportunities on record — a Seminole County, Florida naloxone procurement and a Texas Health and Human Services Commission request for information on direct-to-manufacturer prescription programs — do not represent amosulalol monohydrochloride purchases. State and local governments appear to use this code inconsistently or not at all for purchases of the specific pharmaceutical named. The code does not surface active recent procurement activity for amosulalol monohydrochloride itself.

Activity under this code shows limited issuing-body diversity and geographic concentration. Seminole County and the Texas HHS Commission are the only recent buyers on record; both are exploratory or operational early-stage procurements rather than active contract awards. The Seminole County IFB (No. IFB60459723LAS) closed on July 26, 2023, seeking naloxone and drug deactivation systems with quarterly deliveries, while the Texas RFI (No. HHS0017013) posted April 3, 2026, sought vendor capabilities for a therapeutic pharmacy initiative. Geographic reach is limited to Florida and Texas in the recent record. The code's sparse recent activity and the mismatch between its name and what state and local buyers are actually soliciting suggest this is not a primary procurement channel for this specific pharmaceutical or that it is used only opportunistically when taxonomic alternatives are not available.